skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Encorafenib (Code C98283)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Encorafenib

Definition: An orally available Raf kinase inhibitor with potential antineoplastic activity. Encorafenib specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.

Display Name: Encorafenib

Label: Encorafenib

NCI Thesaurus Code: C98283 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C3273936  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
LGX 818

External Source Codes: 
CAS Registry Number 1269440-17-6 (see NLM ChemIDplus info)
FDA UNII Code 8L7891MRB6
PDQ Closed Trial Search ID 712549
PDQ Open Trial Search ID 712549 (check for NCI PDQ open clinical trial info)
UMLS CUI C3273936

Other Properties:
     Name Value (qualifiers indented underneath)
code C98283
Contributing_Source CTRP
Contributing_Source FDA
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom